Back to search

Boston University

Evaluating the therapeutic and ethical dimensions of psilocybin for major depressive disorder

Abstract

dc:description.abstract

Major depressive disorder (MDD) remains a leading cause of disability worldwide, with many patients experiencing limited response to conventional treatments. Psilocybin, a psychedelic compound found in certain mushroom species, has recently gained clinical interest for its potential to produce rapid and sustained antidepressant effects, particularly among individuals with treatment-resistant depression (TRD). This literature review critically examines current evidence on the mechanisms, clinical outcomes, and therapeutic framework of psilocybin-assisted psychotherapy (PAP) in the treatment of MDD. Acting through serotonergic and glutamatergic pathways, psilocybin appears to promote neuroplasticity, disrupt rigid patterns of negative thinking, and alter neurocircuitry often implicated in depression. When administered in supportive clinical settings, it can facilitate emotional breakthroughs and improve cognitive flexibility, contributing to its therapeutic impact. Studies have shown that even one or two administrations of psilocybin can lead to meaningful reductions in symptoms. Certain methodological limitations remain, such as small sample sizes and narrow inclusion criteria. This review also explores the ethical and practical barriers of clinically integrating PAP, including issues related to informed consent, access, standardization, and therapeutic boundaries. While psilocybin is not a universal solution, it represents a promising avenue for individuals unresponsive to standard care.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2025

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Bhatnagar, Girija
Advisors dc:contributor.advisor
  • Trinkaus Randall, Vickery
  • Graboski, Corrie

Subjects

dc:subject × 4

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53178

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Bhatnagar, Girija. Evaluating the therapeutic and ethical dimensions of psilocybin for major depressive disorder. masters thesis, Boston University, 2025. https://hdl.handle.net/2144/53178